烟酰胺单核苷酸增强靶向 MSLN 的 CAR-NK 细胞治疗在卵巢癌中的抗肿瘤疗效
Nicotinamide mononucleotide potentiates the anti-tumor efficacy of CAR-NK cell therapy targeting MSLN in ovarian cancer.
肿瘤细胞治疗研究
FRONTIER PAPERS
近 5 年肿瘤细胞治疗领域的研究论文。默认按评分排序(权威性 + 新鲜度)。
Nicotinamide mononucleotide potentiates the anti-tumor efficacy of CAR-NK cell therapy targeting MSLN in ovarian cancer.
Chemical priming potentiates mesothelin-targeting chimeric antigen receptor-engineered NK-92 antitumor activity by improving tumor trafficking and cyt
这些发现表明,化学预处理可增强 CAR-NK 细胞功能,并提供了一种有前景的非基因策略来提升 CAR-NK 细胞对实体瘤模型的活性。
Efficacy of chimeric antigen receptor natural killer cells in treatment of ovarian cancer. A meta-analysis of pre-clinical studies.
Current Developments of CAR-T and CAR-NK Cell Therapies for Ovarian Cancer.
Mesothelin as a Signal Pathways and Epigenetic Target in Cancer Therapy.
Neoleukin-2/15-armored CAR-NK cells sustain superior therapeutic efficacy in solid tumors via c-Myc/NRF1 activation.
Repurposing anti-mesothelin CAR-NK immunotherapy against colorectal cancer.
我们的结果提供了临床前证据,表明表达高水平间皮素的结直肠癌亚群可被基于 MSLN-CAR 的免疫治疗有效靶向。
Mesothelin CAR-engineered NK cells derived from human embryonic stem cells suppress the progression of human ovarian cancer in animals.
共 8 条
MEMBER ACCOUNT
登录成功会直接打开下一页。